

**Florida Committee on Trauma - Visiting Professor  
Lecture: Trauma resuscitation and use of whole blood  
Friday, May 3, 2024**

**CONTINUING MEDICAL EDUCATION CREDIT INFORMATION**

**Accreditation**

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of American College of Surgeons and Florida Committee on Trauma. The American College of Surgeons is accredited by the ACCME to provide continuing medical education for physicians.

**AMA PRA Category 1 Credits™**

The American College of Surgeons designates this live activity for a maximum of **1.00 AMA PRA Category 1 Credits™**. Physicians should claim only the credit commensurate with the extent of their participation in the activity.



*Award of CME credits by ACS is based on compliance of the program with the ACCME accreditation requirements and does not imply endorsement by ACS of the content, the faculty, or the sponsor of the program.*

*Successful completion of this CME activity, which includes participation in the evaluation component, enables the learner to earn credit toward the CME of the American Board of Surgery's Continuous Certification program.*

**PROGRAM OBJECTIVES**

At the conclusion of this activity, participants should be able to:

- Discuss the potential benefits of whole blood over component therapy in children requiring massive transfusion.

**DISCLOSURE INFORMATION**

In accordance with the ACCME Accreditation Criteria, the American College of Surgeons must ensure that anyone in a position to control the content of the educational activity (planners and speakers/authors/discussants/moderators) has disclosed all financial relationships with any commercial interest (termed by the ACCME as "ineligible companies", defined below) held in the

last 24 months (see below for definitions). Please note that first authors were required to collect and submit disclosure information on behalf all other authors/contributors, if applicable.

<b>Ineligible Company:</b> The ACCME defines an “ineligible company” as any entity producing, marketing, re-selling, or distributing health care goods or services used on or consumed by patients. Providers of clinical services directly to patients are NOT included in this definition.
<b>Financial Relationships:</b> Relationships in which the individual benefits by receiving a salary, royalty, intellectual property rights, consulting fee, honoraria, ownership interest (e.g., stocks, stock options or other ownership interest, excluding diversified mutual funds), or other financial benefit. Financial benefits are usually associated with roles such as employment, management position, independent contractor (including contracted research), consulting, speaking and teaching, membership on advisory committees or review panels, board membership, and other activities from which remuneration is received, or expected.
<b>Conflict of Interest:</b> Circumstances create a conflict of interest when an individual has an opportunity to affect CME content about products or services of a ineligible company with which he/she has a financial relationship.

The ACCME also requires that ACS manage any reported conflict and eliminate the potential for bias during the educational activity. Any conflicts noted below have been managed to our satisfaction. The disclosure information is intended to identify any commercial relationships and allow learners to form their own judgments. However, if you perceive a bias during the educational activity, please report it on the evaluation.

SPEAKERS / MODERATORS / DISCUSSANTS / AUTHORS	NOTHING TO DISCLOSE	DISCLOSURE		
		COMPANY	ROLE	RECEIVED
Barbara A. Gaines, MD		<i>Teleflex</i>	<i>Advisory Board meeting</i>	<i>Travel reimbursement</i>
PLANNING COMMITTEE / EDITORIAL COMMITTEE	NOTHING TO DISCLOSE	DISCLOSURE		
		COMPANY	ROLE	RECEIVED
Peter A. Pappas, MD, FACS	X			
John M. Draus, Jr., MD, FACS	X			